The Seroepidemiology of Bordetella pertussis Infections: A Study of Persons Ages 1-65 Years

Cattaneo, Laura; Reed, George W.; Haase, David H.; Wills, Morgan J.; Edwards, Kathryn M.

doi:10.1093/infdis/173.5.1256

Cited by 131 publications

(76 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 Data from a seroprevalence study by Cattaneo et al showed a peak in antibody titers at 4 to 6 years of age, coinciding with DTaP booster dosing, followed by a decline, and a second peak between 13 and 17 years of age. 13 Similar findings were documented by the National Health and Nutrition Examination Survey (NHANES), which reported a protracted decline interrupted by a peak in persons aged 40 to 45 years.…”

supporting

confidence: 72%

Pertussis Infection in the United States: Role for Vaccination of Adolescents and Adults

Brooks¹,

Clover²

2006

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Pertussis is the only vaccine-preventable disease on the rise in the United States, with increasing incidence in adolescents and adults related to waning immunity. Although often considered a relatively mild infection in these populations, pertussis can be a serious, potentially deadly illness, particularly in children <12 months old. Infected adolescents and adults serve as a reservoir for disease transmission to young children and infants, who are most vulnerable to severe pertussis and its life-threatening compli- Pertussis is a highly contagious, respiratory disease marked by severe and protracted coughing. Its common name, whooping cough, comes from the "whoop" sound often made when affected persons try to inhale during or after a severe coughing spell. Pertussis is caused by Bordetella pertussis, a small aerobic Gram-negative rod first isolated at the beginning of the 20th century. The organism produces multiple antigenic and biologically active substances that play a role in the clinical illness and elicit an immune response conferring immunity. Recent evidence suggests that immunity from B. pertussis infection, whether vaccine acquired or natural, is not lifelong. In fact, immunity may wane rather quickly, with protection minimal after 10 years.1 Pertussis is associated with substantial morbidity and mortality, especially among the very young and the very old, and imposes an economic burden. About 90% of pertussis-related deaths are in infants Ͻ6 months old.2 Increased rates of pertussisrelated hospitalizations in persons Ͼ50 years may be due to increased risk of pneumonia. 3 Mean medical and nonmedical costs per case in 2002 were $242 and $155, respectively, for adolescents and $326 and $447, respectively, for adults. 4 More than 60% of affected adults miss a mean of 9.8 days from work and over 80% of affected adolescents miss a mean of 5.5 days from school because of pertussis. 4Pertussis remains a public health concern despite availability of an effective diphtheria-tetanusThis article was externally peer-reviewed.

show abstract

supporting

confidence: 72%

Pertussis Infection in the United States: Role for Vaccination of Adolescents and Adults

Brooks¹,

Clover²

2006

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

show abstract

“…1), the group with a lower seroprevalence for B. pertussis consists of subjects between 30 and 34 y of age followed by an increase in those 35-39 y. This increase could be related to differences in the kinetics of PT 36 or to the waning immune response observed 10 to 20 y after natural infection potentially occurring during adolescence, once protection of primary vaccination was lost. 37 The 25 to 29 age group displayed the highest seroprevalence figures.…”

Section: Studymentioning

confidence: 99%

“…These data coincide with that described in several studies conducted in other countries. [36][37][38] As value and negative when absorbance values were less than 15% of the cut-off value. Statistical analysis.…”

Section: Studymentioning

confidence: 99%

Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, andB. Pertussisin young adults of Madrid, Spain

González-Escalada

García-García

Viguera-Ester

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Las razones para el insuficiente control de la enfermedad son varias y complejas e incluyen por un lado la duración limitada de la protección que otorgan las vacunas www.sochinf.cl que va de 4 a 12 años según diferentes estudios 3, [8][9][10] , así como su incapacidad para interrumpir la circulación de Bordetella pertussis 11,12 dado su escaso efecto en portación nasofaríngea del agente. Así mismo, es probable que la presión selectiva que ejercen las vacunas, esté favoreciendo la emergencia de cepas mutantes del microorganismo, con mejores mecanismos patogénicos que logren infectar a individuos vacunados [13][14][15][16] .…”

Section: Causas De Los Brotesunclassified

Estrategias para proteger al recién nacido y lactante menor de 6 meses de la coqueluche: Posición del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología (CCI)

Potı́n¹,

Fíca²,

Véliz³

et al. 2016

Rev. chil. infectol.

View full text Add to dashboard Cite

, en representación del CCI Strategies to protect the newborn and infants under 6 months of age against pertussis. Statement of the Advisory Committee for Immunizations of the Chilean Infectious Diseases SocietyIn recent years there have been Pertussis outbreaks not seen in the last 50 years affecting adults, adolescents and children and causing deaths in young unvaccinated infants. In Chile an outbreak of Pertussis started in year 2011, leaving 16 infants less than 3 months dead during this year, twice the number seen in a non epidemic year. These children were infected before receiving the programmatic vaccines indicated at 2, 4 and 6 months of age, usually from close contacts, especially their mothers. Pertussis control has not been possible for several reasons, such as limited immunity duration of available vaccines and their poor impact on nasopharyngeal carriage, situation that keeps the agent's circulation and transmission, condition often asymptomatic or unrecognized. Additionally, the use of acellular vaccines appears to be a determining factor because they induce an immune response with poor immune memory and consequently a short time duration. The acellular vaccines with reduced antigen content, available for adolescents and adults, has allowed the evaluation of various strategies but none has succeeded in reducing infant mortality. Recently a new strategy of vaccinating pregnant women against Pertussis in the second or third semester has shown remarkable results reducing up to 90% infant deaths due to Pertussis infection. This strategy prevents mother´s infection avoiding child infection through respiratory droplets and also provides the child with antibodies from placental transmission. Improved pertussis vaccines are required, in the meantime the Committee considers that the pregnant immunization strategy, between the 27 and 36 weeks, with acellular pertussis vaccine should be included in our national vaccine program.Key words: Pertussis infection, whooping cough, maternal immunization. Palabras clave: Coqueluche, tos ferina, vacunación materna. Situación epidemiológicaL a coqueluche o tos convulsiva, constituye junto al sarampión, una de las dos enfermedades inmunoprevenibles de mayor transmisibilidad, siendo cada una de ellas capaz de enfermar cerca de 12 a 17 personas susceptibles. A pesar del uso de vacunas eficaces por más de 60 años, la coqueluche continúa siendo un problema de salud pública provocando anualmente unas 200.000 muertes de lactantes en el mundo 1 . En forma cíclica, cada dos a cinco años ocurren brotes epidémicos, incluso en países con altas coberturas de vacunación y entre los años 2010 y 2012 se alcanzaron las incidencias más altas de los últimos 20 a 50 años en países desarrollados como E.U.A. . Estos aumentos de la incidencia afectan a lactantes bajo 6 meses de edad, que por su edad no han iniciado la vacunación o no la han completado o tampoco poseen ya inmunidad pasiva transferida desde la madre. Los brotes también afectan a escolares o adolescentes y adultos, en los que ...

show abstract

The Seroepidemiology of Bordetella pertussis Infections: A Study of Persons Ages 1-65 Years

Cited by 131 publications

References 12 publications

Pertussis Infection in the United States: Role for Vaccination of Adolescents and Adults

Pertussis Infection in the United States: Role for Vaccination of Adolescents and Adults

Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, andB. Pertussisin young adults of Madrid, Spain

Estrategias para proteger al recién nacido y lactante menor de 6 meses de la coqueluche: Posición del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología (CCI)

Contact Info

Product

Resources

About